No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Introduction
Breast cancer is the most common cancer among women (1) . Despite an overall 5-year relative survival rate of almost 90% for breast cancer patients in Sweden (2), it remains the primary cause of cancer death among women world-wide (1) . Though tamoxifen is an effective anti-estrogen treatment for breast cancer patients with estrogen receptor (ER) positive tumors, around 30% of tamoxifen-treated women relapse despite five-years of tamoxifen treatment (3) . Markers of tamoxifen treatment-resistance could allow for more personalized treatment, improving the prognosis for many women (4) .
The cytochrome P2D6 (CYP2D6) enzyme is considered the key enzyme in transforming tamoxifen into one of its most abundant active metabolites, endoxifen (5) . Patients with two non-functional CYP2D6 alleles have lower plasma concentrations of endoxifen than patients with functioning alleles (6, 7) . Hence, it has been proposed that CYP2D6 genotype may be associated with recurrence among tamoxifen-treated breast cancer patients. Several studies have investigated the relationship between the gene encoding cytochrome P450 2D6 (CYP2D6) and tamoxifen treatment outcome, with widely heterogeneous results (4, 5, (8) (9) (10) .
It has been suggested that CYP2D6 inhibitor use, aromatase inhibitor use and chemotherapy may account for some of these discrepancies (5) . Therefore, we examined the association between CYP2D6 genotype and early breast cancer events in tamoxifen-treated breast cancer patients, in relation to CYP2D6 inhibitor use, aromatase inhibitor use, and chemotherapy in a prospective cohort of tamoxifen-treated breast cancer patients in Sweden.
Materials and Methods
The design of the study has been described in detail elsewhere (11) . In brief, preoperative questionnaires on lifestyle and concomitant medications were completed by 634 breast Centre (RSKC Malmö), Malmö University Hospital, Malmö, Sweden, using methods previously described (11) . Over 10% of the samples were run in duplicate with a concordance of 100%. CYP2D6 inhibiting drugs were classified in accordance with
Flockhart et al. (13) . Only the use of the strongest inhibitor was considered. Patients with ER-negative tumors who had received tamoxifen treatment were excluded. Each patient received a CYP2D6 genotype activity score and a CYP2D6 activity score (14, 15) , and was then categorized as poor (PM), intermediate (IM), and extensive metabolizer (EM) (activity scores 0, 0.5-1.5, 2, respectively) (14) .
Breast cancer-free survival was calculated from the pre-operative visit to the last follow-up visit or a non-breast cancer related death, or to a diagnosis of a breast cancer event prior to Jan 1, 2012. Survival analyses were performed using Kaplan-Meier and Cox regression models.
Patients who had received pre-operative treatment (n=17), patients with carcinoma in situ (n=1), patients who lacked CYP2D6 genotype information (n=7), and patients who both received pre-operative treatment and lacked CYP2D6 genotype information (n=1) were excluded from the survival analyses. Survival in relation to combined tamoxifen and CYP2D6
inhibitor use was assessed though landmark analyses (landmark set as treatment-initiation of tamoxifen and CYP2D6 inhibitors within nine months of study entry). A P-value of <0.05 was taken to be significant. All P-values were two-sided.
Results
Patient characteristics for all 634 patients, and for the 333 tamoxifen-treated patients with ER-positive tumors, are presented in Table I . The median follow-up was 4.9 years.
Frequency of the CYP2D6 genotypes, with and without stratification according to CYP2D6
genotype activity score and CYP2D6 activity score, is presented in Table II In the landmark analyses, CYP2D6 activity score (which takes both genotype and CYP2D6
inhibitor use into account) was not associated with early breast cancer events in the univariable (LogRank, P trend =0.44) or in the multivariable model. Tamoxifen treatmentduration was not associated with CYP2D6 genotype, age, aromatase inhibitor or chemotherapy treatment.
Discussion
In this prospective cohort of tamoxifen-treated breast cancer patients in Sweden, there was no evidence that poor CYP2D6 metabolizers had an impaired tamoxifen treatment outcome. In accordance with several previous studies of breast cancer patients in Scandinavia (10, 16, 17) , neither CYP2D6 genotype nor CYP2D6 inhibitor use was associated with early events.
The present study has several strengths. It is population-based (11) and uses Swedish population registries for optimal follow-up. All polymorphisms were analyzed from germline DNA, and multiple polymorphisms were included. Also, blood for genotyping was collected at study entry, and CYP2D6 inhibitor use was collected for the entire cohort of 634 patients.
A total number of 38 patients (6%) used either strong or intermediate CYP2D6 inhibitors, which is comparable to a previous publication (18). The main limitation of the study is the sample size. The number of tamoxifen monotherapy treated patients was relatively small, but the lack of association between CYP2D6 genotype and disease-free survival seen in the present study has also been reported from previous studies conducted in larger cohorts (5, 19) .
CYP2D6 inhibitor use, chemotherapy, or aromatase inhibitor therapy did not account for the absence of an association between CYP2D6 genotype and tamoxifen treatment outcome in this study. Many antidepressants are metabolized by enzymes other than CYP2D6 that are involved in tamoxifen metabolism, such as CYP2C19 (20) and CYP2C8/9 (6, 21). This could in part explain the association between antidepressant use and breast cancer free survival found in previous studies (6, 22) . Other genetic variants (10, 23, 24) , and lifestyle factors such as a high coffee intake, (25) have been associated with survival among tamoxifentreated breast cancer patients in Sweden. CYP2D6 may be of minor importance for prediction of tamoxifen response in Scandinavia (9, 10, 16, 17) .
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